Respicardia Inc has raised at least $5.1 million in a private debt placement after publishing positive results in a pivotal trial for its implantable, pacemaker-like device to treat sleep apnea, reports TwinCities Business.

The latest financing was revealed in Form D regulatory filing. It shows the firm had raised $5.1 million of an expected total of $6.6 million from 13 investors as of June 14, in the form of promissory notes convertible into equity.